Brief: Deciphera Pharmaceuticals Presents Results From The Intrigue Phase 3 Clinical Study At The American Society Of Clinical Oncology Plenary Series Session

Deciphera Pharmaceuticals

24/01/2022 22:08

Jan 24 (Reuters) - Deciphera Pharmaceuticals Inc  DCPH.O :
    * DECIPHERA PHARMACEUTICALS PRESENTS RESULTS FROM THE
INTRIGUE
PHASE 3 CLINICAL STUDY AT THE AMERICAN SOCIETY OF CLINICAL
ONCOLOGY PLENARY SERIES SESSION
    * DECIPHERA - EFFICACY OBSERVED WITH QINLOCK COMPARABLE TO
SUNITINIB WITH MORE FAVORABLE SAFETY, TOLERABILITY PROFILE IN
GIST PATIENTS TREATED WITH IMATINIB
    * DECIPHERA PHARMACEUTICALS INC - INTRIGUE STUDY DID NOT
MEET ITS
PRIMARY ENDPOINT OF SUPERIORITY IN PROGRESSION-FREE SURVIVAL
VERSUS SUNITINIB
    * DECIPHERA PHARMACEUTICALS INC - PROGRESSION-FREE SURVIVAL
OF
QINLOCK DID NOT MEET STUDY'S PRIMARY ENDPOINT OF SUPERIORITY
COMPARED TO SUNITINIB

Source text for Eikon:  ID:nBw7GjkQja 
Further company coverage:  DCPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))